Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:CABA NASDAQ:CUE NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.17-1.0%$4.14$2.93▼$7.55$528.15M1.461.55 million shs1.22 million shsCABACabaletta Bio$3.01$3.36$1.26▼$4.23$490.80M3.213.16 million shs2.91 million shsCUECue Biopharma$24.53-9.4%$138.65$4.97▼$41.42$113.79M2.5290,226 shs86,602 shsPROKProKidney$1.64-1.2%$1.84$0.54▼$7.13$501.42M1.64965,048 shs774,778 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+5.51%+1.69%+1.20%+4.73%+23.46%CABACabaletta Bio-0.99%-14.25%-17.08%-1.63%+72.00%CUECue Biopharma-2.76%-8.60%-7.42%-89.39%-95.29%PROKProKidney-0.60%-10.27%-6.74%-26.22%+77.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$4.17-1.0%$4.14$2.93▼$7.55$528.15M1.461.55 million shs1.22 million shsCABACabaletta Bio$3.01$3.36$1.26▼$4.23$490.80M3.213.16 million shs2.91 million shsCUECue Biopharma$24.53-9.4%$138.65$4.97▼$41.42$113.79M2.5290,226 shs86,602 shsPROKProKidney$1.64-1.2%$1.84$0.54▼$7.13$501.42M1.64965,048 shs774,778 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+5.51%+1.69%+1.20%+4.73%+23.46%CABACabaletta Bio-0.99%-14.25%-17.08%-1.63%+72.00%CUECue Biopharma-2.76%-8.60%-7.42%-89.39%-95.29%PROKProKidney-0.60%-10.27%-6.74%-26.22%+77.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$8.80111.03% UpsideCABACabaletta Bio 2.57Moderate Buy$15.50414.95% UpsideCUECue Biopharma 1.00SellN/AN/APROKProKidney 2.50Moderate Buy$7.40351.22% UpsideCurrent Analyst Ratings BreakdownLatest CUE, PROK, CABA, and AQST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026CABACabaletta Bio Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026PROKProKidney HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/15/2026CABACabaletta Bio Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$2.00 ➝ $4.005/4/2026CABACabaletta Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.004/24/2026AQSTAquestive Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.004/21/2026PROKProKidney Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AQSTAquestive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CABACabaletta Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026CABACabaletta Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $16.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.54M11.75N/AN/A($0.28) per share-14.89CABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/ACUECue Biopharma$27.47M3.75N/AN/A$10.08 per share2.43PROKProKidney$890K556.60N/AN/A($3.36) per share-0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$83.78M-$0.61N/AN/AN/A-137.08%N/A-49.33%8/10/2026 (Estimated)CABACabaletta Bio-$167.86M-$1.96N/AN/AN/AN/A-131.58%-96.46%8/6/2026 (Estimated)CUECue Biopharma-$26.60M-$5.58N/AN/AN/A-59.65%-98.30%-53.69%8/18/2026 (Estimated)PROKProKidney-$68.99M-$0.53N/AN/AN/A-8,131.50%N/A-21.39%8/11/2026 (Estimated)Latest CUE, PROK, CABA, and AQST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PROKProKidney-$0.13-$0.14-$0.01-$0.14$0.10 million$0.23 million5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A5/14/2026Q1 2026CUECue Biopharma-$3.30-$1.08+$2.22-$1.08$2.50 million$5.69 million5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 million3/23/2026Q4 2025CABACabaletta Bio-$0.45-$0.40+$0.05-$0.40N/AN/A3/18/2026Q4 2025PROKProKidney-$0.16-$0.14+$0.02-$0.13$0.00 million$0.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A4.103.85CABACabaletta BioN/A2.952.95CUECue BiopharmaN/A3.573.57PROKProKidneyN/A9.069.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%CABACabaletta BioN/ACUECue Biopharma35.04%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics6.81%CABACabaletta Bio6.44%CUECue Biopharma14.56%PROKProKidney39.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics160125.45 million116.91 millionOptionableCABACabaletta Bio50163.05 million152.55 millionOptionableCUECue Biopharma604.20 million3.59 millionOptionablePROKProKidney3302.06 million181.75 millionOptionableCUE, PROK, CABA, and AQST HeadlinesRecent News About These CompaniesProKidney Corp. (NASDAQ:PROK) Given Average Rating of "Moderate Buy" by AnalystsJune 5, 2026 | americanbankingnews.comProKidney names first chief technology officer as kidney therapy nears pivotal trial readoutJune 2, 2026 | bizjournals.comProKidney Appoints Kenneth Locke as Chief Technical OfficerJune 2, 2026 | globenewswire.comProKidney Shareholders Back Board Picks as Rilparencel Phase 3 Timeline Stays on TrackJune 1, 2026 | americanbankingnews.comProKidney shareholders reaffirm board and auditor at 2026 meetingMay 29, 2026 | tipranks.comProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2026 | zacks.comProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial ResultsMay 15, 2026 | quiverquant.comQProKidney Reports First Quarter 2026 Financial Results and Business HighlightsMay 15, 2026 | globenewswire.comProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for RilparencelMay 2, 2026 | finance.yahoo.comProKidney Corp. Class AApril 14, 2026 | edition.cnn.comApril 2026 Penny Stock HighlightsApril 3, 2026 | finance.yahoo.comWhat Makes ProKidney Corp. (PROK) So AttractiveMarch 31, 2026 | insidermonkey.comWhat makes ProKidney Corp. (PROK) so attractiveMarch 31, 2026 | msn.com5 Best Penny Stocks That Could Triple Your MoneyMarch 30, 2026 | insidermonkey.comProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial OfficerMarch 25, 2026 | globenewswire.comProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy†by BrokeragesMarch 22, 2026 | defenseworld.netDProKidney narrows loss to $150M as it eyes crucial kidney treatment trial resultsMarch 20, 2026 | bizjournals.comTrade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial StabilityMarch 20, 2026 | tipranks.comProKidney Reports Full Year 2025 Financial Results and Business HighlightsMarch 19, 2026 | finance.yahoo.com3 Promising Penny Stocks With At Least $600M Market CapFebruary 12, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCUE, PROK, CABA, and AQST Company DescriptionsAquestive Therapeutics NASDAQ:AQST$4.17 -0.04 (-0.95%) Closing price 04:00 PM EasternExtended Trading$4.22 +0.05 (+1.18%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Cabaletta Bio NASDAQ:CABA$3.01 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.02 +0.02 (+0.50%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Cue Biopharma NASDAQ:CUE$24.53 -2.56 (-9.45%) Closing price 04:00 PM EasternExtended Trading$24.74 +0.20 (+0.84%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.ProKidney NASDAQ:PROK$1.64 -0.02 (-1.20%) Closing price 04:00 PM EasternExtended Trading$1.67 +0.03 (+1.95%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
